Share on StockTwits

XenoPort (NASDAQ:XNPT) Director John Gordon Freund purchased 15,000 shares of the stock on the open market in a transaction dated Friday, May 23rd. The stock was purchased at an average cost of $3.73 per share, with a total value of $55,950.00. Following the acquisition, the director now directly owns 8,899 shares of the company’s stock, valued at approximately $33,193. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

XenoPort (NASDAQ:XNPT) traded up 8.02% during mid-day trading on Tuesday, hitting $4.04. The stock had a trading volume of 630,511 shares. XenoPort has a one year low of $3.15 and a one year high of $7.20. The stock has a 50-day moving average of $3.98 and a 200-day moving average of $5.26. The company’s market cap is $250.0 million.

XenoPort (NASDAQ:XNPT) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.32) by $0.04. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $3.86 million. During the same quarter last year, the company posted ($0.50) earnings per share. XenoPort’s revenue was up 639.1% compared to the same quarter last year. Analysts expect that XenoPort will post $-1.46 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of XenoPort in a research note on Thursday, May 15th. They now have a $6.00 price target on the stock. Separately, analysts at RBC Capital cut their price target on shares of XenoPort from $12.00 to $10.00 in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $6.22.

XenoPort, Inc is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.